Literature DB >> 9792144

Selective suppression of cytokine secretion in whole blood cell cultures of patients with colorectal cancer.

H Lahm1, M Schindel, L Frikart, J P Cerottini, A Yilmaz, J C Givel, J R Fischer.   

Abstract

We have investigated the secretion of interferon alpha (IFN-alpha), IFN-gamma, interleukin-1alpha (IL-1alpha), IL-1beta, IL-2 and tumour necrosis factor alpha (TNF-alpha) in whole blood cell cultures (WBCCs) of colorectal cancer patients upon mitogen stimulation. Whereas the values for IL-1beta and TNF-alpha remained virtually unchanged in comparison with healthy control subjects, WBCCs of colorectal cancer patients secreted significantly lower amounts of IFN-alpha (P < 0.005), IFN-gamma (P < 0.0001), IL-1alpha (P < 0.0001) and IL-2 (P < 0.05). This reduction correlated with the progression of the disease. The total leucocyte and monocyte population were almost identical in both groups. In contrast, a dramatic depletion of lymphocytes was observed in colorectal cancer patients, which affected both lymphocyte counts (P < 0.0005) and their distribution (P < 0.0001). Our results suggest a selective suppression of cytokines in colorectal cancer patients that is related to tumour burden. Several mechanisms might account for this phenomenon, one of which might be lymphocyte depletion.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9792144      PMCID: PMC2063165          DOI: 10.1038/bjc.1998.621

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  18 in total

1.  Regional immunosuppression in esophageal squamous cancer: evidence from functional studies with matched lymph nodes.

Authors:  G C O'Sullivan; A R Corbett; F Shanahan; J K Collins
Journal:  J Immunol       Date:  1996-11-15       Impact factor: 5.422

2.  Ex vivo cytokine production by whole blood cells from cancer patients.

Authors:  D De Groote; Y Gevaert; M Lopez; R Gathy; F Marchal; B Detroz; N Jacquet; V Geenen
Journal:  Cancer Detect Prev       Date:  1996

3.  Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.

Authors:  M Hahne; D Rimoldi; M Schröter; P Romero; M Schreier; L E French; P Schneider; T Bornand; A Fontana; D Lienard; J Cerottini; J Tschopp
Journal:  Science       Date:  1996-11-22       Impact factor: 47.728

4.  Characterization of lung squamous cell carcinoma-derived T-cell suppressive factor.

Authors:  I Yoshino; T Yano; M Miyamoto; K Yamada; Y Kajii; K Onodera; T Ishida; K Sugimachi; G Kimura; K Nomoto
Journal:  Cancer       Date:  1993-10-15       Impact factor: 6.860

5.  Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression.

Authors:  G A Gastl; J S Abrams; D M Nanus; R Oosterkamp; J Silver; F Liu; M Chen; A P Albino; N H Bander
Journal:  Int J Cancer       Date:  1993-08-19       Impact factor: 7.396

6.  Constitutive secretion of bioactive transforming growth factor beta 1 by small cell lung cancer cell lines.

Authors:  J R Fischer; H Darjes; H Lahm; M Schindel; P Drings; P H Krammer
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

7.  Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor.

Authors:  I Yoshino; T Yano; M Murata; T Ishida; K Sugimachi; G Kimura; K Nomoto
Journal:  Cancer Res       Date:  1992-02-15       Impact factor: 12.701

8.  Evaluation of a test system for measuring cytokine production in human whole blood cell cultures.

Authors:  U Elsässer-Beile; S von Kleist; H Gallati
Journal:  J Immunol Methods       Date:  1991-06-03       Impact factor: 2.303

9.  Contact-dependent stimulation of monocytic cells and neutrophils by stimulated human T-cell clones.

Authors:  J M Li; P Isler; J M Dayer; D Burger
Journal:  Immunology       Date:  1995-04       Impact factor: 7.397

10.  The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.

Authors:  J O'Connell; G C O'Sullivan; J K Collins; F Shanahan
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

View more
  2 in total

1.  Combined treatment with bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patients.

Authors:  Nikolaos Tsavaris; Ioannis F Voutsas; Christos Kosmas; Angelos D Gritzapis; Constantin N Baxevanis
Journal:  Invest New Drugs       Date:  2010-09-07       Impact factor: 3.850

2.  The pattern of cytokine gene expression in human colorectal carcinoma.

Authors:  Anna Csiszár; Tamás Szentes; Bea Haraszti; Annamária Balázs; Gyôzô G Petrányi; Eva Pócsik
Journal:  Pathol Oncol Res       Date:  2004-06-09       Impact factor: 2.874

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.